Aspira Women’s Health (NASDAQ:AWH) Coverage Initiated at StockNews.com

Research analysts at StockNews.com began coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a note issued to investors on Monday. The firm set a “hold” rating on the stock.

Separately, Alliance Global Partners dropped their price objective on Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating for the company in a report on Wednesday, August 14th.

Aspira Women’s Health Price Performance

AWH opened at $0.75 on Monday. Aspira Women’s Health has a fifty-two week low of $0.67 and a fifty-two week high of $5.65. The company has a market cap of $12.50 million, a price-to-earnings ratio of -0.62 and a beta of 1.44. The firm has a 50 day simple moving average of $0.84 and a 200 day simple moving average of $1.31.

Institutional Trading of Aspira Women’s Health

A hedge fund recently raised its stake in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. raised its holdings in Aspira Women’s Health Inc. (NASDAQ:AWH) by 88.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 236,396 shares of the company’s stock after acquiring an additional 111,022 shares during the period. B. Riley Wealth Advisors Inc. owned about 1.90% of Aspira Women’s Health worth $352,000 as of its most recent filing with the Securities and Exchange Commission. 12.19% of the stock is currently owned by hedge funds and other institutional investors.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.